Alkermes Revenue 2006-2021 | ALKS

Alkermes annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Alkermes revenue for the quarter ending June 30, 2021 was $0.304B, a 22.7% increase year-over-year.
  • Alkermes revenue for the twelve months ending June 30, 2021 was $1.100B, a 5.3% decline year-over-year.
  • Alkermes annual revenue for 2020 was $1.039B, a 11.29% decline from 2019.
  • Alkermes annual revenue for 2019 was $1.171B, a 7.01% increase from 2018.
  • Alkermes annual revenue for 2018 was $1.094B, a 21.13% increase from 2017.
Alkermes Annual Revenue
(Millions of US $)
2020 $1,039
2019 $1,171
2018 $1,094
2017 $903
2016 $746
2015 $628
2014 $619
2013 $433
2013 $576
2012 $390
2011 $187
2010 $178
2009 $327
2008 $241
2007 $240
2006 $167
2005 $76
Alkermes Quarterly Revenue
(Millions of US $)
2021-06-30 $304
2021-03-31 $251
2020-12-31 $280
2020-09-30 $265
2020-06-30 $248
2020-03-31 $246
2019-12-31 $413
2019-09-30 $255
2019-06-30 $280
2019-03-31 $223
2018-12-31 $316
2018-09-30 $249
2018-06-30 $305
2018-03-31 $225
2017-12-31 $275
2017-09-30 $217
2017-06-30 $219
2017-03-31 $192
2016-12-31 $214
2016-09-30 $180
2016-06-30 $195
2016-03-31 $157
2015-12-31 $163
2015-09-30 $153
2015-06-30 $151
2015-03-31 $161
2014-12-31 $175
2014-09-30 $160
2014-06-30 $153
2014-03-31 $130
2013-12-31 $154
2013-09-30 $140
2013-06-30 $139
2013-03-31 $163
2012-12-31 $136
2012-09-30 $124
2012-06-30 $152
2012-03-31 $130
2011-12-31 $126
2011-09-30 $72
2011-06-30 $62
2011-03-31
2010-12-31 $44
2010-09-30 $49
2010-06-30 $42
2010-03-31
2009-12-31 $44
2009-09-30 $48
2009-06-30 $47
2009-03-31
2008-12-31 $156
2008-09-30 $47
2008-06-30 $80
2008-03-31
2007-12-31 $51
2007-09-30 $59
2007-06-30 $69
2007-03-31
2006-12-31 $62
2006-09-30 $61
2006-06-30 $52
2006-03-31
2005-12-31 $41
2005-09-30 $47
2005-06-30 $25
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.176B $1.039B
Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29